Shionogi To Pay 60% Premium For Sciele Pharma

September 2008 | M&A News Alert

The fourth Japanese outbound pharmaceutical deal in less than a year was announced on September 2 by Shionogi. The prescription drug firm said that it will buy US-based Sciele Pharma for US$1.4bn. Shionogi will pay US$31 a share for Sciele, a premium of 57% to Sciele's six-month share price up to August 29, and a 61% premium to its August 29 closing price.

If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Corporate Financing Week please click on the trial link below.